Fang L, Ford-Roshon D, Russo M, et al. RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition. Nat Commun. 2022;13(1):3181. doi:10.1038/s41467-022-30794-7
Shen J, Xiao R, Bair J, et al. Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study. Cell Death Dis. 2018;9(10):1018. doi:10.1038/s41419-018-1049-0
Koyama S, Yu H, Dalgarno DC, Shin TB, Zydowsky LD, Schreiber SL. 1H and 15N assignments and secondary structure of the PI3K SH3 domain. FEBS Lett. 1993;324(1):93-8.
Van Stry M, Kazlauskas A, Schreiber SL, Symes K. Distinct effectors of platelet-derived growth factor receptor-alpha signaling are required for cell survival during embryogenesis. Proc Natl Acad Sci U S A. 2005;102(23):8233-8. doi:10.1073/pnas.0502885102
Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell. 1994;76(5):933-45.
Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756-8. doi:10.1038/369756a0
Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell. 1995;82(1):121-30.
Abazeed ME, Adams DJ, Hurov KE, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73(20):6289-98. doi:10.1158/0008-5472.CAN-13-1616
Shamji AF, Nghiem P, Schreiber SL. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell. 2003;12(2):271-80.
Yang J, Shamji A, Matchacheep S, Schreiber SL. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol. 2007;14(4):371-7. doi:10.1016/j.chembiol.2007.02.004